AI assistant
PFIZER INC — Director's Dealing 2022
Mar 1, 2022
29831_dirs_2022-03-01_582a487e-2051-4032-b28e-12bf05c200b7.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: PFIZER INC (PFE)
CIK: 0000078003
Period of Report: 2022-02-26
Reporting Person: DAMELIO FRANK A (Executive Vice President)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-02-26 | Common Stock | M | 127160.0000 | $25.6000 | Acquired | 649918.0000 | Direct |
| 2022-02-26 | Common Stock | F | 34607.0000 | $47.7200 | Disposed | 615311.0000 | Direct |
| 2022-02-26 | Common Stock | F | 59370.0000 | $50.6400 | Disposed | 555941.0000 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-02-26 | Stock Appreciation Rights | $25.6000 | M | 127160.0000 | Disposed | 2022-02-26 | Common Stock (127160.0000) | Direct |
Footnotes
F1: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).
F2: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.
F3: Price is the closing price of Pfizer common stock on February 25, 2022.
F4: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).
F5: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.